Keith Wheatley

40.2k total citations · 11 hit papers
254 papers, 27.0k citations indexed

About

Keith Wheatley is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Keith Wheatley has authored 254 papers receiving a total of 27.0k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Hematology, 77 papers in Molecular Biology and 55 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Keith Wheatley's work include Acute Myeloid Leukemia Research (106 papers), Acute Lymphoblastic Leukemia research (51 papers) and Retinoids in leukemia and cellular processes (35 papers). Keith Wheatley is often cited by papers focused on Acute Myeloid Leukemia Research (106 papers), Acute Lymphoblastic Leukemia research (51 papers) and Retinoids in leukemia and cellular processes (35 papers). Keith Wheatley collaborates with scholars based in United Kingdom, France and United States. Keith Wheatley's co-authors include Richard Gray, Alan K. Burnett, Richard Peto, Richard Doll, I. L. G. Sutherland, Anthony H. Goldstone, Robert K. Hills, Ian Hann, David Grimwade and Helen M. Walker and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Keith Wheatley

249 papers receiving 26.0k citations

Hit Papers

Mortality in relation to smoking: 40 years' observations ... 1988 2026 2000 2013 1994 1998 2010 2001 1994 1000 2.0k 3.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Mortality in relation to smoking: 40 years' observations on male British doctors
    1994 3.9k citations Richard Doll, Richard Peto et al. BMJ profile →
  2. The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
    1998 2.1k citations David Grimwade, Helen M. Walker et al. Blood profile →
  3. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
    2010 1.3k citations David Grimwade, Robert K. Hills et al. Blood profile →
  4. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials
    2001 1.2k citations G Harrison, Stephen E. Langabeer et al. Blood profile →
  5. Mortality in relation to consumption of alcohol: 13 years' observations on male British doctors
    1994 928 citations Richard Doll, Richard Peto et al. BMJ profile →
  6. Association between premature mortality and hypopituitarism
    2001 817 citations Jeremy Tomlinson, N Holden et al. The Lancet profile →
  7. Randomised trial of prophylactic daily aspirin in British male doctors
    1988 795 citations Richard Peto, Richard Gray et al. BMJ profile →
  8. Hydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
    2005 610 citations Claire Harrison, Peter J. Campbell et al. profile →
  9. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial
    2010 522 citations Natalie Ives, Keith Wheatley et al. profile →
  10. Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
    2010 490 citations Alan K. Burnett, Robert K. Hills et al. Journal of Clinical Oncology profile →
  11. Physiotherapy versus placebo or no intervention in Parkinson's disease
    2013 327 citations Carl E Clarke, Rebecca Stowe et al. Cochrane Database of Systematic Reviews profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Keith Wheatley United Kingdom 74 13.4k 7.8k 6.5k 4.8k 3.9k 254 27.0k
Frits R. Rosendaal Netherlands 101 18.9k 1.4× 2.3k 0.3× 3.6k 0.6× 4.4k 0.9× 1.1k 0.3× 806 41.4k
Leslie L. Robison United States 123 4.3k 0.3× 6.5k 0.8× 24.3k 3.8× 5.1k 1.1× 10.8k 2.7× 936 58.3k
María E. Suarez‐Almazor United States 79 4.9k 0.4× 2.0k 0.3× 2.9k 0.4× 1.3k 0.3× 4.4k 1.1× 404 24.1k
Dafna D. Gladman Canada 102 13.6k 1.0× 2.7k 0.4× 1.2k 0.2× 734 0.2× 1.9k 0.5× 959 47.9k
Melissa M. Hudson United States 94 1.8k 0.1× 2.6k 0.3× 13.7k 2.1× 2.7k 0.6× 7.1k 1.8× 760 34.5k
Steve E. Humphries United Kingdom 94 3.6k 0.3× 7.9k 1.0× 1.9k 0.3× 898 0.2× 2.2k 0.6× 872 42.3k
Piet L. C. M. van Riel Netherlands 69 6.3k 0.5× 1.9k 0.2× 733 0.1× 2.6k 0.5× 1.4k 0.4× 328 24.1k
Vibeke Strand United States 73 5.6k 0.4× 1.5k 0.2× 969 0.1× 2.0k 0.4× 1.5k 0.4× 522 22.9k
Tore K Kvien Norway 84 5.4k 0.4× 2.2k 0.3× 1.0k 0.2× 1.5k 0.3× 1.1k 0.3× 537 28.6k
Michael H. Weisman United States 67 5.0k 0.4× 2.2k 0.3× 783 0.1× 1.9k 0.4× 1.3k 0.3× 340 22.2k

Countries citing papers authored by Keith Wheatley

Since Specialization
Citations

This map shows the geographic impact of Keith Wheatley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith Wheatley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith Wheatley more than expected).

Fields of papers citing papers by Keith Wheatley

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith Wheatley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith Wheatley. The network helps show where Keith Wheatley may publish in the future.

Co-authorship network of co-authors of Keith Wheatley

This figure shows the co-authorship network connecting the top 25 collaborators of Keith Wheatley. A scholar is included among the top collaborators of Keith Wheatley based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith Wheatley. Keith Wheatley is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Green, Darren, et al.. (2024). Long Term Outcomes After Renal Revascularization for Atherosclerotic Renovascular Disease in the ASTRAL Trial. Circulation Cardiovascular Interventions. 17(9). e013979–e013979. 2 indexed citations
2.
3.
4.
5.
Sackley, Catherine, Marion Walker, Christopher R Burton, et al.. (2015). An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial. BMJ. 350(feb05 23). h468–h468. 40 indexed citations
6.
Burnett, Alan K., Nigel H. Russell, Robert K. Hills, et al.. (2013). Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial. Journal of Clinical Oncology. 31(27). 3360–3368. 289 indexed citations
7.
Bate, Jessica, Julia Chisholm, Paul T. Heath, et al.. (2011). PEPtalk: postexposure prophylaxis against varicella in children with cancer. Archives of Disease in Childhood. 96(9). 841–845. 12 indexed citations
8.
Grimwade, David, Robert K. Hills, Anthony V. Moorman, et al.. (2010). Refinement of cytogenetic classification in acute myeloid leukaemia: Determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. British Journal of Haematology. 149. 17–17. 29 indexed citations
9.
Stowe, Rebecca, Natalie Ives, Carl E Clarke, et al.. (2010). Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson´s disease patients with motor complications. Cochrane Database of Systematic Reviews. 2010(7). CD007166–CD007166. 78 indexed citations
10.
Grimwade, David, Robert K. Hills, Anthony V. Moorman, et al.. (2009). REFINEMENT OF CYTOGENETIC CLASSIFICATION IN AML: DETERMINATION OF PROGNOSTIC SIGNIFICANCE OF RARE RECURRING CHROMOSOMAL ABNORMALITIES AMONGST 5635 YOUNGER ADULTS TREATED IN THE UK MRC TRIALS. Haematologica. 94. 217–217. 5 indexed citations
11.
Stowe, Rebecca, Natalie Ives, Carl E Clarke, et al.. (2008). Dopamine agonist therapy in early Parkinson's disease. Cochrane Database of Systematic Reviews. 2010(1). CD006564–CD006564. 147 indexed citations
12.
Grimwade, David, Anthony V. Moorman, Robert K. Hills, et al.. (2004). Impact of karyotype on treatment outcome in acute myeloid leukemia.. Annals of Hematology. 83. 17 indexed citations
13.
Harrison, Christine J., Anthony V. Moorman, Robert K. Hills, et al.. (2003). Cytogenetics of childhood AML from UK medical research council treatment trials, AML10 & 12.. Blood. 102(11). 333–333. 3 indexed citations
14.
Tomlinson, Jeremy, et al.. (2001). Association between premature mortality and hypopituitarism. The Lancet. 357(9254). 425–431. 817 indexed citations breakdown →
15.
Harrison, G, et al.. (2000). Relationships between age at diagnosis, clinical features and outcome of therapy in children treated in the Medical Research Council trials for acute myeloid leukemia AML 10 and 12.. Blood. 96. 2 indexed citations
16.
Grimwade, David, et al.. (1999). The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.. British Journal of Haematology. 105. 67–67. 5 indexed citations
17.
18.
Burnett, Alan K., et al.. (1997). Outcome of acute myeloid leukaemias affecting core binding factor subunits: the UK MRC experience. ORCA Online Research @Cardiff (Cardiff University). 1 indexed citations
19.
Wheatley, Keith, Alan K. Burnett, A H Goldstone, et al.. (1995). A simple, robust and highly predictive prognostic index for the determination of risk directed therapy in acute myeloid leukaemia (AML) derived from the United Kingdom medical research council (MRC) AML10 trial.. Blood. 86. 2381–2381. 13 indexed citations
20.
Hennekens, C H, J. E. Buring, Peter Sandercock, et al.. (1990). Aspirin use and chronic diseases. BMJ. 300(6717). 117.2–118. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frits R. Rosendaal Breakdown of academic impact, for papers by Leslie L. Robison Breakdown of academic impact, for papers by María E. Suarez‐Almazor Breakdown of academic impact, for papers by Dafna D. Gladman Breakdown of academic impact, for papers by Melissa M. Hudson Breakdown of academic impact, for papers by Steve E. Humphries Breakdown of academic impact, for papers by Piet L. C. M. van Riel Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Tore K Kvien Breakdown of academic impact, for papers by Michael H. Weisman
Rankless by CCL
2026